Intensity Therapeutics, Inc. (INTS)
4.26
+0.01
(+0.24%)
USD |
NASDAQ |
Aug 31, 15:09
Intensity Therapeutics EPS Diluted (Quarterly) : -1.111 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.111 |
| March 31, 2026 | -0.9606 |
| December 31, 2025 | -1.208 |
| September 30, 2025 | -1.551 |
| June 30, 2025 | -3.362 |
| March 31, 2025 | -0.2206 |
| December 31, 2024 | -5.436 |
| September 30, 2024 | -0.2545 |
| June 30, 2024 | -0.3625 |
| March 31, 2024 | -0.3358 |
| December 31, 2023 | -0.2314 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.1699 |
| June 30, 2023 | -0.2825 |
| March 31, 2023 | -0.102 |
| December 31, 2022 | -0.1153 |
| September 30, 2022 | -0.1355 |
| June 30, 2022 | -0.1472 |
| March 31, 2022 | -0.1808 |
| December 31, 2021 | -0.1833 |
| March 31, 2021 | -0.1129 |
| December 31, 2020 | -0.1248 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0749 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.007M |
| Total Expenses (Quarterly) | 3.007M |
| Enterprise Value | 3.085M |
| Earnings Yield | -113.4% |
| Normalized Earnings Yield | -113.42 |